A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Inclusion Criteria: * This study will evaluate MK0457 in patients with CML (chronic myelogenous leukemia) and Ph+ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia) * Patients must have adequate organ function * Patients must have documented T315I mutation Exclusion Criteria: * Patients within 3 months of allogeneic bone marrow transplant or not fully recovered from previous anti-leukemia therapy * Patients with uncontrolled congestive heart failure * Patients with active or uncontrolled infection or active Hepatitis B or C * Patients with known HIV positivity or AIDS related illness * Patients with currently active second malignancy, other than non-melanoma skin cancer.